Lexapro Patent Upheld On Appeal

Law360, New York (September 5, 2007, 12:00 AM EDT) -- A federal appeals court panel has upheld both the validity of Forest Laboratories Inc.’s patent on the blockbuster antidepressant drug Lexapro and an injunction thwarting Ivax Pharmaceuticals Corp.’s plans to market a generic.

The U.S. Court of Appeals for the Federal Circuit ruled Wednesday that the lower court correctly rejected Ivax's argument that the patent was anticipated, obvious and impermissibly broadened upon re-issue.

“We agree with Forest that the district court’s factual findings ... are not clearly erroneous, and, based upon those findings, we find no...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.